Otsuka Pharmaceutical Europe Ltd clinical trials

A country office of Otsuka Holdings Co., Ltd.

The registry lists 8 studies whose lead sponsor is Otsuka Pharmaceutical Europe Ltd. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 11, 2019.

Studies

Recruiting first, then most recently updated. Showing 8 of 8. All Otsuka Holdings Co., Ltd. studies →

• Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset SchizophreniaStatus unknownNCT03130465

  Sponsor listed in the registry: Otsuka Pharmaceutical Europe Ltd

• A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in EuropeStatus unknownNCT02848521

  Sponsor listed in the registry: Otsuka Pharmaceutical Europe Ltd

• Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in SpainCompletedNCT03130478

  Sponsor listed in the registry: Otsuka Pharmaceutical Europe Ltd

• An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in SpainCompletedNCT02548845

  Sponsor listed in the registry: Otsuka Pharmaceutical Europe Ltd

• An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in ItalyCompletedNCT02573077

  Sponsor listed in the registry: Otsuka Pharmaceutical Europe Ltd

• An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADHCompletedNCT02545101

  Sponsor listed in the registry: Otsuka Pharmaceutical Europe Ltd

• Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in ItalyCompletedNCT03005769

  Sponsor listed in the registry: Otsuka Pharmaceutical Europe Ltd

• Adacolumn in Refractory UC Patients TrialCompletedNCT01481142Phase 4

  Sponsor listed in the registry: Otsuka Pharmaceutical Europe Ltd